Trichinella spiralis: Knockdown of gamma interferon inducible lysosomal thiol reductase (GILT) results in the reduction of worm burden

Trichinella spiralis is mammalian skeletal muscles parasite which may cause trichinellosis in animals and humans. Gamma interferon inducible lysosomal thiol reductase (GILT) is a widespread superfamily which plays key role in processing and presentation of MHC class II restricted antigen by catalyzing disulfide bond reduction. There are no reports about GILT in T. spiralis. In present study, GILT from T. spiralis (Tsp-GILT) was cloned, analyzed by multiple-sequence alignment, and predicted by 3D structure model. Recombinant Tsp-GILT (about 46 kDa) was efficiently expressed in Escherichia coli and thiol reductase activity suggested that in acidic environment the addition of a reducing agent is needed. Soaking method was used to knockdown expression of Tsp-GILT using small interference RNA (siRNA). Immunofluorescence assay confirmed the transformation of siRNA into muscle larva (ML) and new born larva (NBL). Quantitative real time-PCR (QRT-PCR) analysis revealed that transcription level of Tsp-GILT mRNA can be up-regulated by stimulation of mouse IFN-γ and down-regulated by siRNA2 in vitro. NBLs soaked with siRNA2 showed 32.3% reduction in the generation of MLs. MLs soaked with siRNA2 showed 26.2% reduction in the next generation of MLs, but no significant effect was observed on adult worms or NBLs. These findings concluded that GILT may play important roles in the development of T. spiralis parasite.

Preliminary Exploration of the Stimulating Effect of Pomalidomide on BCMA-CART in the Treatment of Multiple Myeloma Patients

Research Background: BCMA-CART treatment can give patients with relapsed and refractory multiple myeloma a chance of remission, but because the patient's own lymphocytes are poor in number and function, poor autologous CART cell expansion or failure to expand will affect the efficacy of CART. It is necessary to explore ways to improve the curative effect of CART so as to increase the remission rate. Research purposes The purpose of the study was to observe the changes in symptoms, signs, and vital signs of patients with pomalidomide in the early stage after BCMA-CART reinfusion, analyze the changes in cytokines and CART expansion after oral pomalidomide, and summarize the symptoms of such patients Disease remission rate and survival status. Research methods Collect the clinical characteristics of patients who took pomalidomide orally within one month after BCMA-CART cell reinfusion in our hospital from January 2019 to July 2021, and count the symptoms and signs of patients with pomalidomide before and after CART. Compare the values of cytokine and CART cell expansion before and after CART reinfusion to explore the synergistic effect of pomalidomide with CART. Research result From January 2019 to July 2021, a total of 5 patients with multiple myeloma who took pomalidomide orally within 1 month after BCMA-CART cell reinfusion were treated in our department from January 2019 to July 2021. There were 2 male patients and 3 female patients. The median age is 63 years (35-70). The median number of patients' previous treatment lines is 7 (3-18), of which 3 patients(3/5) have had previous autologous hematopoietic stem cell transplantation. The number of reinfused BCMA-CART cells in 5 patients was 8.13 (0.11-16.5)*105/kg, the median time of oral pomalidomide was 14 (8-19) days of CART reinfusion, and the dose was 1 case (1/ 5) 4 mg 1/day for patients, 2 mg 1/day for 3 patients (3/5), 1 mg 1/5 for 1 patient (1/5); 3 patients (3/5) before pomalidomide treatment ). The number of CART cell expansion in patients was 0.00%, 0.40% in 1 case (1/5), and 7.03% in 1 case (1/5). None of them had fever. 4 patients (4/5) had fever after taking pomalidomide, the median maximum body temperature was 38.95 (38.3-40.2) ℃, and the fever occurred 1.5 (1-4) days after taking pomalidomide; The amplification of CART cells of all patients can be detected by PCR method after pomalidomide, and the start time of amplification is 5 (2-8) days after taking pomalidomide; the amplification of CART cells The highest peak occurred at 9 (4-19) days after taking pomalidomide. The peak of CART cell expansion increased by 3.86 (0.06-37.8)% compared to before treatment with pomalidomide; the CRS classification after taking pomalidomide of 4 cases (4/5) were grade 2 and 1 case (1/5) was grade 3, of which 2 cases (2/5) had ICANS. Cytokines were increased in all patients after pomalidomide. Among them, IL-6 of all cases (5/5) increased after pomalidomide, and the highest value of IL-6 appeared after pomalidomide. At 9 (5-22) days after pomalidomide administration, the increase value was 20.60 (16.16-380.23) pg/mL; among the 4 patients that can be counted, TNF-α level of 4 patients (4/4) were increased after pomalidomide administration, the highest value of TNF-α appeared at 7.5 (6-8) days after pomalidomide administration, and the increase value was 21.825 (11.60-32.81) pg/mL. All 4 countable patients had higher soluble CD25 after pomalidomide administration, and the highest value of soluble CD25 appeared 11 (6-14) days after pomalidomide administration, and the value of increase was 7987 (3765-26173) pg/Ml. Gamma interferon of all 4 countable patients increased after pomalidomide administration, and the highest value of gamma interferon appeared in 9.5 (2-14) days after pomalidomide use, the increase value was 18.49 (5.3-587.8) pg/ml. The efficacy of 5 patients evaluated after 1 month after BCMA-CART was 2 cases (2/5) with stable disease, 2 cases (2/5) with partial remission, and 1 case (2/5) with disease progression. As of the deadline for submission, 5 patients are currently alive, and the median OS is 113 (42-236) days after CART reinfusion. Analysis conclusion Pomalidomide can promote the expansion and activation of CART and stimulate the release of cytokines in the early stage after BCMA-CART treatment. Whether it can enhance the anti-tumor effect of CART remains to be further studied. Disclosures No relevant conflicts of interest to declare.

Using of Gamma Interferon γ-IFN and Multiplex PCR (m-PCR) for Detection of Bovine Tuberculosis in Dairy Herds in Egypt

Many diagnostic tools are essential for Mycobacterium bovis (M. bovis) eradication program. This study aimed to apply γ-IFN assay to detect bovine tuberculosis and multiplex PCR (m-PCR) for rapid identification of Mycobacterial isolates. A total no. of 150 cattle in 10 small farms at different Governorates in Egypt, were previously gave suspected results with comparative cervical tuberculin test (SICCT), they retested after 60 days later again with SICCT and bovine gamma-interferon (γ-IFN) immunoassay. Eighty-seven (58%) out of total 150 animals were +ve reactors by SICCT test while 80 (53.3%) animals gave +ve γ-IFN assay. The isolated M. bovis by conventional culturing and identification tests were +ve 55 (63.2%) out 87. The γ-IFN assay sensitivity and specificity gave 82.9% and 93.8% respectively. For rapid identification of different mycobacterial isolates using m-PCR two set of primers were used. The first set gave 123bp DNA PCR product expressing IS6110 insertion element for Mycobacterium tuberculosis (MTBC). The other one gave 500bp from RvD1Rv2031c genomic sequence definite to M. bovis. M-PCR findings were in a concordance with results of conventional culturing and identification tests with high sensitivity and specificity (100%). From this study, it is concluded that diagnosis of bovine tuberculosis (BTB) used tuberculin test and γ-IFN assay with m-PCR for rapid identification M. bovis isolates in living herds.

Gamma-interferon inducible lysosomal thiolreductase (GILT) effect on breast tumor microenvironment through regulating CXCR6/CXCL16 axis.

e15081 Background: Gamma-interferon Inducible Lysosomal Thiolreductase (GILT) is constitutively expressed in most antigens endocytosed by antigen presenting cells (APCs), and its function is to catalyze the reduction of disulfide (S-S) bonds in protein substrates. The cytokine CXCL16 is one of the only two known plasma membrane chemokines which induces chemotaxis of activated T cells and bone marrow plasma cells in tumor microenvironment. It contains a free end folded by two sulfur bonds and therefore could also be a zymolyte of GILT. Previous studies found that specific receptor of CXCL16, CXCR6, was significantly overexpressed in breast cancer tissues and metastatic axillary lymph nodes. We suppose whether CXCR6/CXCL16 axis is regulated by GILT and affect tumor microenvironment, thereby eliciting specific anti-tumor immune responses in breast cancer (BC). Methods: GILT expression in BC was evaluated using publicly available data from The Cancer Genome Atlas (TCGA). GILT gene was analyzed in UALCAN ( http://ualcan.path.uab.edu/analysis-prot.html ) . In vitro, Immunohistochemistry (IHC) was conducted to examine the location and relation of GILT and CXCR6. Gene Set Enrichment Analysis (GSEA) was performed to mine the biological pathways involved in BC related GILT regulatory network. The expression of GILT at protein and RNA levels were detected by Western Blot and RT-PCR assay. Overexpression and knockdown of GILT in BC cell lines was carried out to further analyzed the correlation between GILT and CXCL16/CXCR6. Results: TCGA database showed that GILT expression was increased in the stroma of BC compared with normal, and was correlated to shorter BC overall survival. GSEA suggested that the expression of GILT was associated with chemotactic factors. Pearson analysis and IHC showed GILT had a strong correlation with CXCL16/CXCR6 axis in the aspect of angiogenesis and immunity. qRT-PCR and Western Blot assay also revealed that GILT had high expression in BC. Besides, patients with high expression of GILT in IHC simultaneously showed high immunoreactive to macrophage markers, which was related to neovascularization and anti-tumor immune responses. Compared with the normal breast cell line MCF-10A, GILT protein had high expression in Hs578T and low expression in MDA-MB-231 cell line. GILT was overexpressed in MDA-MB-231 and knockdown in Hs578T. Result showed that high level GILT promoted the production of CXCL16/CXCR6,while GILT siRNA knockdown inhibited the production of CXCL16/CXCR6. Conclusions: GILT could catalyze CXCL16 in BC, function as a key mechanism to affect tumor microenvironment through CXCR6/CXCL16 pathway. GILT-activated CXCL16 levels showed a strong connection with unfavorable outcomes in BC, which could be a potential biomarker of prognosis and a novel therapeutic target.

Effect of Chocolate Soybean Drink on Nutritional Status, Gamma Interferon, Vitamin D, and Calcium in Newly Lung Tuberculosis Patients

BACKGROUND: Tuberculosis (TB) is an infectious disease associated with malnutrition and high risk to morbidity and mortality, especially when it was not supplied with a balanced diet. This study aimed to assess the effect of chocolate soybean drink (CSD) on nutritional status, gamma interferon (IFN-γ), Vitamin D, and calcium level in newly diagnosed pulmonary TB patients. AIM: This study aimed to assess the effect of chocolate soybean milk to nutritional status, interferon-gamma level, Vitamin D level, and sputum conversion in lung TB patients. METHODS: Quasi-experimental design pre- and post-test control was performed on 34 patients who were divided into two groups, each consisting of 17 people. The intervention group received 100 grams CSD per day and nutritional education, while the control group was only given nutritional education for 30 days. A 24-h food recall was performed to record any nutritional intake in the past 24 h. The nutritional status was determined by anthropometric measurements. Laboratory examination was performed to analyze the IFN-γ _level, Vitamin D, and calcium level. RESULTS: Study showed a significant increasing in body weight (p = 0.000), BMI (p = 0.000), IFN-γ _levels (p = 0.001), and not significant on MUAC (p = 0.716). Vitamin D was increased in the intervention group and decreased in the control group. Calcium intake was higher in the intervention compared to the control group (456.6 vs. 151.3) and significantly different (p = 0.000), while sputum BTA conversion was found higher in the intervention group than in the control group and not significantly different between groups (47.1% vs. 17.6%). CONCLUSION: It was concluded that CSD could increase nutritional status (BMI), IFN-γ, Vitamin D, and calcium level in patients with pulmonary TB.